Skip to Content

VanEck Pharmaceutical ETF PPH

Medalist Rating as of | See VanEck Investment Hub

Morningstar’s Analysis PPH

Will PPH outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

VanEck Pharmaceutical ETF’s management team is rated Average, but a solid investment process still helps this strategy retain its Morningstar Medalist Rating of Bronze.

null Morningstar Manager Research

Morningstar Manager Research

Summary

The portfolio maintains a cost advantage over competitors, priced within the lowest fee quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings PPH

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 59.8
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Eli Lilly and Co

10.84 55.2 Mil
Healthcare

Novo Nordisk A/S ADR

8.37 42.6 Mil
Healthcare

Johnson & Johnson

6.31 32.1 Mil
Healthcare

Merck & Co Inc

5.72 29.1 Mil
Healthcare

AbbVie Inc

5.59 28.4 Mil
Healthcare

Novartis AG ADR

4.68 23.8 Mil
Healthcare

Cencora Inc

4.67 23.7 Mil
Healthcare

GSK PLC ADR

4.60 23.4 Mil
Healthcare

McKesson Corp

4.53 23.0 Mil
Healthcare

AstraZeneca PLC ADR

4.45 22.7 Mil
Healthcare